What is Cryo-Cell Intl Inc's earnings per share (EPS)?

Cryo-Cell Intl Inc (CCEL) reported diluted earnings per share of $-0.30 for fiscal year 2025. This represents a -700.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cryo-Cell Intl Inc Financials

CCEL

Source SEC Filings (10-K/10-Q) Updated Nov 30, 2025 Currency USD FYE November

This page shows Cryo-Cell Intl Inc (CCEL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Cryo-Cell Intl Inc has an operating margin of 1.5%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 26/100, suggesting thin profitability after operating expenses. This is down from 10.9% the prior year.

Growth

Cryo-Cell Intl Inc's revenue declined 1.3% year-over-year, from $32.0M to $31.6M. This contraction results in a growth score of 31/100.

Liquidity

Cryo-Cell Intl Inc's current ratio of 0.59 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 6/100, which could limit financial flexibility.

Cash Flow

Cryo-Cell Intl Inc converts 16.6% of revenue into free cash flow ($5.2M). This strong cash generation earns a score of 67/100.

Altman Z-Score Distress

-0.27

Cryo-Cell Intl Inc scores -0.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($29.3M) relative to total liabilities ($80.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

6/9

Cryo-Cell Intl Inc passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-2.26x

For every $1 of reported earnings, Cryo-Cell Intl Inc generates $-2.26 in operating cash flow ($5.5M OCF vs -$2.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

0.2x

Cryo-Cell Intl Inc earns $0.2 in operating income for every $1 of interest expense ($482K vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$31.6M

YoY-1.3%

5Y CAGR+0.3%

10Y CAGR+4.1%

Cryo-Cell Intl Inc generated $31.6M in revenue in fiscal year 2025. This represents a decrease of 1.3% from the prior year.

EBITDA

$1.5M

YoY-64.8%

5Y CAGR-28.8%

10Y CAGR-7.0%

Cryo-Cell Intl Inc's EBITDA was $1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 64.8% from the prior year.

Net Income

-$2.4M

YoY-704.2%

Cryo-Cell Intl Inc reported -$2.4M in net income in fiscal year 2025. This represents a decrease of 704.2% from the prior year.

EPS (Diluted)

$-0.30

YoY-700.0%

Cryo-Cell Intl Inc earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 700.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$5.2M

YoY+45.5%

5Y CAGR-8.9%

10Y CAGR+1.0%

Cryo-Cell Intl Inc generated $5.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.5% from the prior year.

Cash & Debt

$319K

YoY-43.1%

5Y CAGR-50.1%

10Y CAGR-22.6%

Cryo-Cell Intl Inc held $319K in cash against $8.4M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY-0.3%

5Y CAGR+1.3%

10Y CAGR-1.1%

Cryo-Cell Intl Inc had 8M shares outstanding in fiscal year 2025. This represents a decrease of 0.3% from the prior year.

Margins & Returns

Gross Margin

76.6%

YoY+1.5pp

5Y CAGR+7.6pp

Cryo-Cell Intl Inc's gross margin was 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the prior year.

Operating Margin

1.5%

YoY-9.3pp

5Y CAGR-23.1pp

10Y CAGR-12.4pp

Cryo-Cell Intl Inc's operating margin was 1.5% in fiscal year 2025, reflecting core business profitability. This is down 9.3 percentage points from the prior year.

Net Margin

-7.7%

YoY-9.0pp

5Y CAGR-19.3pp

10Y CAGR-46.1pp

Cryo-Cell Intl Inc's net profit margin was -7.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$376K

YoY-69.7%

5Y CAGR+73.6%

10Y CAGR+23.4%

Cryo-Cell Intl Inc invested $376K in research and development in fiscal year 2025. This represents a decrease of 69.7% from the prior year.

Share Buybacks

$170K

YoY-88.1%

10Y CAGR-25.5%

Cryo-Cell Intl Inc spent $170K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 88.1% from the prior year.

Capital Expenditures

$230K

YoY-90.4%

5Y CAGR+18.2%

10Y CAGR+7.8%

Cryo-Cell Intl Inc invested $230K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.4% from the prior year.

CCEL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$31.6M-1.3%	$32.0M+2.0%	$31.3M+3.3%	$30.3M+5.0%	$28.9M-7.3%	$31.1M
Cost of Revenue	$7.4M-7.2%	$7.9M-5.3%	$8.4M-4.6%	$8.8M-2.2%	$9.0M-6.9%	$9.7M
Gross Profit	$24.2M+0.6%	$24.0M+4.7%	$23.0M+6.5%	$21.5M+8.3%	$19.9M-7.4%	$21.5M
R&D Expenses	$376K-69.7%	$1.2M+6.1%	$1.2M+204.4%	$385K+671.6%	$50K+109.1%	$24K
SG&A Expenses	$18.2M-1.6%	$18.5M+7.9%	$17.2M+10.2%	$15.6M+6.6%	$14.6M+2.2%	$14.3M
Operating Income	$482K-86.1%	$3.5M+128.3%	-$12.3M-405.7%	$4.0M+0.2%	$4.0M-47.6%	$7.7M
Interest Expense	$2.1M+10.8%	$1.9M+50.8%	$1.2M-18.7%	$1.5M+10.4%	$1.4M-10.7%	$1.5M
Income Tax	$92K-96.2%	$2.4M+162.5%	-$3.8M-801.8%	$548K+3.8%	$528K-62.7%	$1.4M
Net Income	-$2.4M-704.2%	$402K+104.2%	-$9.5M-443.6%	$2.8M+33.0%	$2.1M-42.5%	$3.6M
EPS (Diluted)	$-0.30-700.0%	$0.05+104.4%	$-1.14-445.5%	$0.33+32.0%	$0.25-44.4%	$0.45

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$7.8M+0.2%	$7.8M-1.3%	$7.9M-0.5%	$8.0M-0.7%	$8.0M-0.5%	$8.1M+0.3%	$8.0M+2.4%	$7.9M
Cost of Revenue	$1.7M-3.7%	$1.8M-3.0%	$1.9M-6.5%	$2.0M+14.7%	$1.7M-18.6%	$2.1M+5.0%	$2.0M-2.0%	$2.1M
Gross Profit	$6.1M+1.4%	$6.0M-0.8%	$6.1M+1.5%	$6.0M-4.9%	$6.3M+5.9%	$5.9M-1.3%	$6.0M+4.0%	$5.8M
R&D Expenses	$85K+37.6%	$62K-53.2%	$132K+34.2%	$98K-67.8%	$305K+57.1%	$194K-19.6%	$241K-52.1%	$503K
SG&A Expenses	$5.4M+40.6%	$3.9M-9.0%	$4.3M-8.2%	$4.6M-21.6%	$5.9M+42.1%	$4.2M+3.6%	$4.0M-9.3%	$4.4M
Operating Income	-$4.0M-308.7%	$1.9M+27.3%	$1.5M+41.3%	$1.1M+963.1%	-$122K-108.8%	$1.4M-0.1%	$1.4M+69.4%	$821K
Interest Expense	$482K-10.5%	$538K-2.3%	$551K+11.3%	$495K-33.6%	$745K+39.7%	$533K+62.0%	$329K+28.4%	$256K
Income Tax	-$815K-286.6%	$437K+99.1%	$219K-12.6%	$251K-75.4%	$1.0M+210.5%	$328K-59.8%	$816K+242.6%	$238K
Net Income	-$3.8M-609.4%	$749K+110.6%	$356K+25.8%	$283K+115.2%	-$1.9M-277.0%	$1.1M+60.4%	$656K+17.9%	$556K
EPS (Diluted)	N/A	$0.09+125.0%	$0.04+33.3%	$0.03	N/A	$0.13+62.5%	$0.08+14.3%	$0.07

CCEL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$61.7M-4.6%	$64.7M0.0%	$64.7M-0.3%	$64.9M+7.0%	$60.7M+31.3%	$46.2M
Current Assets	$11.8M-6.3%	$12.6M+32.8%	$9.5M-1.6%	$9.6M-39.1%	$15.8M-14.9%	$18.6M
Cash & Equivalents	$319K-43.1%	$561K+38.1%	$406K-76.2%	$1.7M-79.4%	$8.3M-20.2%	$10.4M
Inventory	$409K-37.8%	$658K-14.5%	$769K-9.7%	$851K-7.6%	$921K-0.7%	$927K
Accounts Receivable	$6.8M-6.3%	$7.3M+11.1%	$6.6M+8.8%	$6.0M+15.1%	$5.3M-16.9%	$6.3M
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$80.3M+3.1%	$77.9M+7.8%	$72.3M+8.8%	$66.4M+17.6%	$56.5M+15.6%	$48.9M
Current Liabilities	$19.8M-8.4%	$21.6M+3.5%	$20.9M+7.1%	$19.5M-7.6%	$21.1M+28.4%	$16.4M
Long-Term Debt	$8.4M-1.5%	$8.5M-1.3%	$8.6M-1.5%	$8.7M+360.0%	$1.9M-68.1%	$5.9M
Total Equity	-$18.6M-40.8%	-$13.2M-19.8%	-$11.0M-623.7%	-$1.5M-136.4%	$4.2M+257.0%	-$2.7M
Retained Earnings	-$38.4M-17.3%	-$32.8M-5.2%	-$31.2M-44.0%	-$21.6M-29.3%	-$16.7M+11.1%	-$18.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$61.7M-2.3%	$63.2M-2.0%	$64.4M+0.1%	$64.4M-0.5%	$64.7M+2.8%	$62.9M+0.6%	$62.6M+1.4%	$61.7M
Current Assets	$11.8M+0.7%	$11.7M-10.6%	$13.1M+4.3%	$12.5M-0.4%	$12.6M+17.8%	$10.7M+5.0%	$10.2M+7.5%	$9.5M
Cash & Equivalents	$319K+20.3%	$265K+92.9%	$137K-38.4%	$223K-60.2%	$561K+184.1%	$197K-57.9%	$469K+89.9%	$247K
Inventory	$409K-37.6%	$655K-3.2%	$677K-7.4%	$730K+11.1%	$658K-10.1%	$731K+3.3%	$708K-6.2%	$755K
Accounts Receivable	$6.8M+0.2%	$6.8M-1.4%	$6.9M-3.9%	$7.2M-1.3%	$7.3M+6.3%	$6.9M+0.6%	$6.8M+1.6%	$6.7M
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$80.3M+3.0%	$78.0M-2.5%	$80.0M+1.2%	$79.0M+1.5%	$77.9M+7.4%	$72.5M-1.1%	$73.3M+1.7%	$72.0M
Current Liabilities	$19.8M+7.3%	$18.5M-15.2%	$21.8M+0.1%	$21.7M+0.6%	$21.6M+24.0%	$17.4M-10.4%	$19.4M+0.4%	$19.4M
Long-Term Debt	$8.4M-0.4%	$8.4M-0.4%	$8.4M-0.4%	$8.5M-0.3%	$8.5M-0.3%	$8.5M-0.3%	$8.5M-0.4%	$8.6M
Total Equity	-$18.6M-25.4%	-$14.8M+4.7%	-$15.6M-6.2%	-$14.7M-10.9%	-$13.2M-38.3%	-$9.6M+11.0%	-$10.7M-3.9%	-$10.3M
Retained Earnings	-$38.4M-11.0%	-$34.6M+2.1%	-$35.4M-2.5%	-$34.5M-5.3%	-$32.8M-13.4%	-$28.9M+3.5%	-$29.9M+2.1%	-$30.6M

CCEL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$5.5M-8.9%	$6.0M-32.6%	$8.9M+4.0%	$8.6M+8.2%	$7.9M-6.4%	$8.5M
Capital Expenditures	$230K-90.4%	$2.4M-64.9%	$6.8M-43.8%	$12.2M+563.5%	$1.8M+1734.7%	$100K
Free Cash Flow	$5.2M+45.5%	$3.6M+73.4%	$2.1M+157.9%	-$3.6M-159.0%	$6.1M-27.2%	$8.4M
Investing Cash Flow	-$975K+80.0%	-$4.9M+40.1%	-$8.1M+46.7%	-$15.3M-119.8%	-$7.0M-2044.5%	$357K
Financing Cash Flow	-$4.7M-384.6%	-$979K+52.8%	-$2.1M-1501.9%	$148K+104.8%	-$3.1M+38.6%	-$5.0M
Dividends Paid	$3.2M+59.9%	$2.0M	$0-100.0%	$7.7M	$0	N/A
Share Buybacks	$170K-88.1%	$1.4M+78.2%	$799K-56.1%	$1.8M+629.8%	$249K	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$1.3M-49.5%	$2.5M+258.8%	$707K-25.9%	$954K-55.8%	$2.2M-11.5%	$2.4M+37.4%	$1.8M+597.0%	-$357K
Capital Expenditures	$67K+73.3%	$39K-37.8%	$62K+0.6%	$62K+643.3%	$8K-95.5%	$186K-89.4%	$1.8M+282.8%	$458K
Free Cash Flow	$1.2M-51.4%	$2.5M+287.5%	$645K-27.7%	$892K-58.5%	$2.1M-4.6%	$2.3M+10348.7%	$22K+102.6%	-$815K
Investing Cash Flow	-$290K-126.2%	$1.1M+173.5%	-$1.5M-422.7%	-$287K+74.2%	-$1.1M-67.6%	-$666K+75.8%	-$2.8M-707.7%	-$341K
Financing Cash Flow	-$937K+73.3%	-$3.5M-594.8%	$710K+170.7%	-$1.0M-48.2%	-$678K+66.8%	-$2.0M-269.8%	$1.2M+123.2%	$539K
Dividends Paid	$0	$0-100.0%	$1.2M-40.1%	$2.0M0.0%	$2.0M	$0	$0	$0
Share Buybacks	$0-100.0%	$81K-8.7%	$89K	$0	$0-100.0%	$16K-98.7%	$1.2M+626.1%	$170K

CCEL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	76.6%+1.5pp	75.1%+1.9pp	73.2%+2.2pp	71.0%+2.1pp	68.9%-0.1pp	69.0%
Operating Margin	1.5%-9.3pp	10.9%+50.1pp	-39.3%-52.5pp	13.3%-0.6pp	13.9%-10.7pp	24.6%
Net Margin	-7.7%-9.0pp	1.3%+31.6pp	-30.4%-39.5pp	9.1%+1.9pp	7.2%-4.4pp	11.6%
Return on Equity	N/A	N/A	N/A	N/A	49.8%	N/A
Return on Assets	-3.9%-4.6pp	0.6%+15.3pp	-14.7%-19.0pp	4.3%+0.8pp	3.4%-4.4pp	7.8%
Current Ratio	0.59+0.0	0.58+0.1	0.45-0.0	0.49-0.3	0.75-0.4	1.13
Debt-to-Equity	-0.45+0.2	-0.64+0.1	-0.78+4.9	-5.73-6.2	0.45+2.7	-2.23
FCF Margin	16.6%+5.4pp	11.3%+4.6pp	6.6%+18.5pp	-11.8%-32.9pp	21.1%-5.8pp	26.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	77.9%+0.9pp	77.0%+0.4pp	76.6%+1.5pp	75.1%-3.3pp	78.4%+4.8pp	73.7%-1.2pp	74.8%+1.1pp	73.7%
Operating Margin	-50.6%-74.9pp	24.3%+5.5pp	18.8%+5.6pp	13.3%+14.8pp	-1.5%-18.8pp	17.2%-0.1pp	17.3%+6.8pp	10.5%
Net Margin	-48.7%-58.3pp	9.6%+5.1pp	4.5%+0.9pp	3.5%+26.8pp	-23.2%-36.2pp	13.0%+4.9pp	8.2%+1.1pp	7.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-6.2%-7.4pp	1.2%+0.6pp	0.5%+0.1pp	0.4%+3.3pp	-2.9%-4.5pp	1.7%+0.6pp	1.1%+0.2pp	0.9%
Current Ratio	0.59-0.0	0.63+0.0	0.60+0.0	0.580.0	0.58-0.0	0.61+0.1	0.52+0.0	0.49
Debt-to-Equity	-0.45+0.1	-0.57-0.0	-0.54+0.0	-0.58+0.1	-0.64+0.2	-0.89-0.1	-0.79+0.0	-0.83
FCF Margin	15.5%-16.4pp	31.9%+23.8pp	8.1%-3.1pp	11.2%-15.6pp	26.8%-1.1pp	27.9%+27.6pp	0.3%+10.6pp	-10.4%

Note: Shareholder equity is negative (-$18.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.59), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Basel Medical Group Ltd BMGL

$11.5M

$17.0M

$8.9M

$1.2M

$6.2M

Frequently Asked Questions

What is Cryo-Cell Intl Inc's annual revenue?

Cryo-Cell Intl Inc (CCEL) reported $31.6M in total revenue for fiscal year 2025. This represents a -1.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cryo-Cell Intl Inc's revenue growing?

Cryo-Cell Intl Inc (CCEL) revenue declined by 1.3% year-over-year, from $32.0M to $31.6M in fiscal year 2025.

Is Cryo-Cell Intl Inc profitable?

No, Cryo-Cell Intl Inc (CCEL) reported a net income of -$2.4M in fiscal year 2025, with a net profit margin of -7.7%.

What is Cryo-Cell Intl Inc's EBITDA?

Cryo-Cell Intl Inc (CCEL) had EBITDA of $1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cryo-Cell Intl Inc have?

As of fiscal year 2025, Cryo-Cell Intl Inc (CCEL) had $319K in cash and equivalents against $8.4M in long-term debt.

What is Cryo-Cell Intl Inc's gross margin?

Cryo-Cell Intl Inc (CCEL) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cryo-Cell Intl Inc's operating margin?

Cryo-Cell Intl Inc (CCEL) had an operating margin of 1.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cryo-Cell Intl Inc's net profit margin?

Cryo-Cell Intl Inc (CCEL) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cryo-Cell Intl Inc's free cash flow?

Cryo-Cell Intl Inc (CCEL) generated $5.2M in free cash flow during fiscal year 2025. This represents a 45.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cryo-Cell Intl Inc's operating cash flow?

Cryo-Cell Intl Inc (CCEL) generated $5.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cryo-Cell Intl Inc's total assets?

Cryo-Cell Intl Inc (CCEL) had $61.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cryo-Cell Intl Inc's capital expenditures?

Cryo-Cell Intl Inc (CCEL) invested $230K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cryo-Cell Intl Inc spend on research and development?

Cryo-Cell Intl Inc (CCEL) invested $376K in research and development during fiscal year 2025.

Does Cryo-Cell Intl Inc buy back shares?

Yes, Cryo-Cell Intl Inc (CCEL) spent $170K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Cryo-Cell Intl Inc have outstanding?

Cryo-Cell Intl Inc (CCEL) had 8M shares outstanding as of fiscal year 2025.

What is Cryo-Cell Intl Inc's current ratio?

Cryo-Cell Intl Inc (CCEL) had a current ratio of 0.59 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Cryo-Cell Intl Inc's debt-to-equity ratio?

Cryo-Cell Intl Inc (CCEL) had a debt-to-equity ratio of -0.45 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cryo-Cell Intl Inc's return on assets (ROA)?

Cryo-Cell Intl Inc (CCEL) had a return on assets of -3.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Cryo-Cell Intl Inc's debt-to-equity ratio negative or unusual?

Cryo-Cell Intl Inc (CCEL) has negative shareholder equity of -$18.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Cryo-Cell Intl Inc's Altman Z-Score?

Cryo-Cell Intl Inc (CCEL) has an Altman Z-Score of -0.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cryo-Cell Intl Inc's Piotroski F-Score?

Cryo-Cell Intl Inc (CCEL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cryo-Cell Intl Inc's earnings high quality?

Cryo-Cell Intl Inc (CCEL) has an earnings quality ratio of -2.26x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cryo-Cell Intl Inc cover its interest payments?

Cryo-Cell Intl Inc (CCEL) has an interest coverage ratio of 0.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cryo-Cell Intl Inc?

Cryo-Cell Intl Inc (CCEL) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.